Jade Biosciences, Inc. Operating Expenses
Jade Biosciences, Inc. (JBIO) reported Operating Expenses of $58.92 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-10
- Jade Biosciences, Inc. operating expenses for the quarter ending 2026-06-30 was $58.92M, a 112.10% increase year-over-year.
- Jade Biosciences, Inc. operating expenses for the quarter ending 2026-03-31 was $43.45M, a 85.79% increase year-over-year.
- Jade Biosciences, Inc. operating expenses for the quarter ending 2025-12-31 was $34.98M, a 75.04% increase year-over-year.
- Jade Biosciences, Inc. operating expenses for the quarter ending 2025-09-30 was $27.40M, a 83.10% increase year-over-year.
- Jade Biosciences, Inc. operating expenses for fiscal 2025 was $113.54M, a 52.21% increase from fiscal 2024.
- Jade Biosciences, Inc. operating expenses for fiscal 2024 was $74.60M, a 8.37% decline from fiscal 2023.
- Jade Biosciences, Inc. operating expenses for fiscal 2023 was $81.41M, a 52.92% increase from fiscal 2022.
- Jade Biosciences, Inc. operating expenses for fiscal 2022 was $53.24M, a 131.24% increase from fiscal 2021.
| Period end | Operating Expenses 0 month | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $58.92M 10-Q · filed 2026-08-10 | $102.36M 10-Q · filed 2026-08-10 | $137.34M derived: sum of 3 quarters · filed 2026-08-10 | $164.74M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2026-03-31 | $43.45M 10-Q · filed 2026-05-07 | $78.42M derived: sum of 2 quarters · filed 2026-05-07 | $105.83M derived: sum of 3 quarters · filed 2026-05-07 | $133.60M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-12-31 | $34.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $62.38M derived: sum of 2 quarters · filed 2026-03-06 | $90.16M derived: sum of 3 quarters · filed 2026-08-10 | $113.54M 10-K · filed 2026-03-06 | ||
| 2025-09-30 | $27.40M 10-Q · filed 2025-11-14 | $55.18M derived: sum of 2 quarters · filed 2026-08-10 | $78.56M 10-Q · filed 2025-11-14 | $98.55M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-06-30 | $27.78M 10-Q · filed 2026-08-10 | $51.16M 10-Q · filed 2026-08-10 | $71.14M derived: sum of 3 quarters · filed 2026-08-10 | $86.70M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-03-31 | $23.38M 10-Q · filed 2026-05-07 | $3.39M 10-Q · filed 2025-04-25 | $43.37M derived: sum of 2 quarters · filed 2026-05-07 | $58.92M derived: sum of 3 quarters · filed 2026-05-07 | $85.09M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $19.98M derived: 10-K 6 month − 10-Q 3 month · filed 2026-03-06 | $35.54M 10-K · filed 2026-03-06 | $61.70M derived: sum of 3 quarters · filed 2026-03-06 | $74.60M 10-K · filed 2025-03-27 | ||
| 2024-09-30 | $14.96M 10-Q · filed 2025-11-14 | $17.41M 10-Q · filed 2024-11-12 | $41.72M derived: sum of 2 quarters · filed 2025-11-14 | $68.19M 10-Q · filed 2024-11-12 | $88.40M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | $590.00K 10-Q · filed 2025-08-13 | $26.16M 10-Q · filed 2024-08-12 | $50.78M 10-Q · filed 2024-08-12 | $72.85M derived: sum of 3 quarters · filed 2025-04-25 | $94.22M derived: sum of 4 quarters · filed 2025-04-25 | |
| 2024-03-31 | $24.62M 10-Q · filed 2025-04-25 | $46.68M derived: sum of 2 quarters · filed 2025-04-25 | $68.05M derived: sum of 3 quarters · filed 2025-04-25 | $88.39M derived: sum of 4 quarters · filed 2025-04-25 | ||
| 2023-12-31 | $22.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $43.43M derived: sum of 2 quarters · filed 2025-03-27 | $63.77M derived: sum of 3 quarters · filed 2025-03-27 | $81.41M 10-K · filed 2025-03-27 | ||
| 2023-09-30 | $21.37M 10-Q · filed 2024-11-12 | $41.70M derived: sum of 2 quarters · filed 2024-11-12 | $59.34M 10-Q · filed 2024-11-12 | $75.19M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $20.34M 10-Q · filed 2024-08-12 | $37.98M 10-Q · filed 2024-08-12 | $53.83M derived: sum of 3 quarters · filed 2024-08-12 | $67.98M derived: sum of 4 quarters · filed 2024-08-12 | ||
| 2023-03-31 | $17.64M 10-Q · filed 2024-05-13 | $33.49M derived: sum of 2 quarters · filed 2024-05-13 | $47.64M derived: sum of 3 quarters · filed 2024-05-13 | $59.86M derived: sum of 4 quarters · filed 2024-05-13 | ||
| 2022-12-31 | $15.85M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $30.00M derived: sum of 2 quarters · filed 2024-03-25 | $42.22M derived: sum of 3 quarters · filed 2024-03-25 | $53.24M 10-K · filed 2024-03-25 | ||
| 2022-09-30 | $14.15M 10-Q · filed 2023-11-13 | $26.37M derived: sum of 2 quarters · filed 2023-11-13 | $37.38M 10-Q · filed 2023-11-13 | $45.65M derived: sum of 4 quarters · filed 2023-11-13 | ||
| 2022-06-30 | $12.21M 10-Q · filed 2023-08-14 | $23.23M 10-Q · filed 2023-08-14 | $31.50M derived: sum of 3 quarters · filed 2023-08-14 | $37.70M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $11.02M 10-Q · filed 2023-05-15 | $19.29M derived: sum of 2 quarters · filed 2023-05-15 | $25.49M derived: sum of 3 quarters · filed 2023-05-15 | $31.26M derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2021-12-31 | $8.27M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $14.47M derived: sum of 2 quarters · filed 2023-03-29 | $20.24M derived: sum of 3 quarters · filed 2023-03-29 | $23.02M 10-K · filed 2023-03-29 | ||
| 2021-09-30 | $6.20M 10-Q · filed 2022-11-14 | $11.97M derived: sum of 2 quarters · filed 2022-11-14 | $14.75M 10-Q · filed 2022-11-14 | $18.42M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $5.77M 10-Q · filed 2022-08-15 | $8.55M 10-Q · filed 2022-08-15 | $12.22M derived: sum of 3 quarters · filed 2022-08-15 | $14.46M derived: sum of 4 quarters · filed 2022-08-15 | ||
| 2021-03-31 | $2.78M 10-Q · filed 2022-05-16 | $6.44M derived: sum of 2 quarters · filed 2022-05-16 | $8.69M derived: sum of 3 quarters · filed 2022-05-16 | $10.31M derived: sum of 4 quarters · filed 2022-05-16 | ||
| 2020-12-31 | $3.66M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $5.91M derived: sum of 2 quarters · filed 2022-03-30 | $7.53M derived: sum of 3 quarters · filed 2022-03-30 | $8.89M 10-K · filed 2022-03-30 | ||
| 2020-09-30 | $2.24M 10-Q · filed 2021-11-15 | $3.87M derived: sum of 2 quarters · filed 2021-11-15 | $5.23M 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | $1.63M 10-Q · filed 2021-08-16 | $2.98M 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |